Search Result

Results for "

P2X2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) CXCR (1) Farnesyl Transferase (1) Fluorescent Dye (1) Glutamate Dehydrogenase (GLDH) (1) Guanylate Cyclase (1) HIV (1) Interleukin Related (1) Isotope-Labeled Compounds (1) NTPDase (1) P2X Receptor (26) P2Y Receptor (3) Reference Standards (1) Small Interfering RNA (siRNA) (3) Sodium Channel (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (6) Infection (1) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (13)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136254

BzATP triethylammonium salt Maximum Cited Publications 14 Publications Verification	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium salt acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium salt is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-112461A

NF449 octasodium 4 Publications Verification	P2X Receptor	Cardiovascular Disease
NF449 octasodium is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 octasodium is a G_sα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-15568

A-317491 5 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A-317491 is a potent, selective and non-nucleotide antagonist of P2X₃ and P2X_2/3 receptors, with K_is of 22, 22, 9, and 92 nM for hP2X₃, rP2X₃, hP2X_2/3, and rP2X_2/3, respectively. A-317491 is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 reduces inflammatory and neuropathic pain by blocking P2X₃ and P2X_2/3 receptor-mediated calcium flux .

HY-14483

AF-353 1 Publications Verification Ro-4	P2X Receptor	Cancer
AF-353 (Ro-4) is a potent, selective and orally bioavailable *P2X3/P2X2/3 receptor* antagonist, with a pIC₅₀ of 8.0 for both human and rat P2X3, and with a pIC₅₀ of 7.3 for human P2X2/3 .

HY-137451

Sivopixant 1 Publications Verification S-600918	P2X Receptor	Neurological Disease
Sivopixant (S-600918) is a potent and selective P2X3 receptor antagonist (P2X3 IC₅₀=4.2 nM; P2X2/3 IC₅₀=1100 nM). Sivopixant shows strong analgesic effect .

HY-D0976

NF279 1 Publications Verification	P2X Receptor HIV NTPDase CXCR	Infection
NF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC₅₀ value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection .

HY-112461

NF449	P2X Receptor	Cardiovascular Disease
NF449 is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 is a G_sα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-108667

TNP-ATP triethylammonium	P2X Receptor Interleukin Related Fluorescent Dye	Neurological Disease
TNP-ATP triethylammonium is a P2X receptor antagonist with an IC₅₀ of 0.010 μM for P2X₃ and an IC₅₀ of 0.062 μM for *P2X_2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA* autophosphorylation, with a K_i of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of P2X_1-7 receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline .

HY-108676

NF023 hexasodium 1 Publications Verification	P2X Receptor	Neurological Disease
NF023 hexasodium is a selective and competitive P2X₁ receptor antagonist, with IC₅₀ values of 0.21 μM, 28.9 μM, > 50 μM and > 100 μM for human P2X₁, P2X₃, P2X₂, and P2X₄-mediated responses respectively .

HY-101308A

MRS2179 tetrasodium hydrate 2 Publications Verification	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium hydrate inhibits platelet aggregation .

HY-135976

P2X3 antagonist 34	P2X Receptor	Neurological Disease Inflammation/Immunology
P2X3 antagonist 34 is a potent, selective and orally active P2X3 homotrimeric receptor antagonist with IC₅₀s of 25 nM, 92 nM and 126 nM for human P2X3, rat P2X3 and guinea pig P2X3 receptors, respectively. P2X3 antagonist 34 is less active against human, rat and guinea pig P2X2/3 heterotrimeric receptors. P2X3 antagonist 34 has strong anti-tussive effect .

HY-16322A

Minodronic acid hydrate 1 Publications Verification YM-529 hydrate	P2X Receptor Apoptosis	Cancer
Minodronic acid (YM-529) hydrate is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic *P2X2/3* receptors involved in pain .

HY-15568A

A-317491 sodium salt hydrate 5 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of P2X₃ and P2X_2/3 receptors, with K_is of 22, 22, 9, and 92 nM for hP2X₃, rP2X₃, hP2X_2/3, and rP2X_2/3, respectively. A-317491 sodium salt hydrate is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 sodium salt hydrate reduces inflammatory and neuropathic pain by blocking P2X₃ and P2X_2/3 receptor-mediated calcium flux .

HY-16322

Minodronic acid 1 Publications Verification YM-529	P2X Receptor Apoptosis Farnesyl Transferase	Metabolic Disease Cancer
Minodronic acid is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .

HY-18745

BzATP triethylammonium Benzoylbenzoyl-ATP triethylammonium	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-19978

RO-3	P2X Receptor	Neurological Disease
RO-3 is a potent, and orally active P2X₃ and *P2X_2/3* antagonist with pIC₅₀s of 5.9 and 7.0 for human homomultimeric P2X₃ and heteromultimeric P2X_2/3 receptors, respectively. RO-3 shows selectivity for P2X₃ and P2X_2/3 over all other functional homomultimeric P2X receptors (IC₅₀ >10 μM at P2X_1,2,4,5,7) .

HY-101308

MRS2179 tetrasodium	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium inhibits platelet aggregation .

HY-108673

Ro 0437626	P2X Receptor	Cancer
Ro 0437626 is a selective purinergic (P2X₁) receptor antagonist (IC₅₀ = 3 μM), but shows low affinity for P2X2, P2X3 and P2X2/3 receptors (IC₅₀ > 100 μM) .

HY-153548

P2X2/3 modulator-1	P2X Receptor	Neurological Disease Inflammation/Immunology
P2X2/3 modulator-1 (Compound 46) is a *P2X2/3* modulator. P2X2/3 modulator-1 can be used in the study of pain, central nervous system disorders and inflammation .

HY-137610A

TNP-ATP tetrasodium	P2X Receptor P2Y Receptor	Neurological Disease
TNP-ATP is an antagonist of purinergic P2Y1, P2X3, and *P2X2/3* receptors (IC₅₀ = 6, 0.9, and 7 nM, respectively, in HEK293 cells expressing human receptors). TNP-ATP reduces acetate-induced calcium flux in 1321N1 cells expressing P2X3 and P2X2/3 receptors (IC₅₀ = 100 and 62 nM, respectively). TNP-ATP dose-dependently attenuates acetate-induced abdominal contractions in a mouse visceral pain model (ED₅₀ = 6.35 µmol/kg) ^[1][2].

HY-P1441A

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

HY-14485

Ro-51	P2X Receptor	Neurological Disease
Ro-51 is a potent and selective dual P2X₃/P2X_2/3 antagonist, with IC₅₀ of 2 nM and 5 nM for P2X₃ and P2X_2/3, respectively. Ro-51 can be used for the research for pain .

HY-14483A

AF-353 hydrochloride Ro-4 hydrochloride	P2X Receptor	Cancer
AF-353 hydrochloride is a potent, selective and orally bioavailable *P2X3/P2X2/3 receptor* antagonist, with a pIC₅₀ of 8.0 for both human and rat P2X3, and with a pIC₅₀ of 7.3 for human P2X2/3 .

HY-14483R

AF-353 (Standard) Ro-4 (Standard)	P2X Receptor Reference Standards	Cancer
AF-353 (Standard) is the analytical standard of AF-353. This product is intended for research and analytical applications. AF-353 (Ro-4) is a potent, selective and orally bioavailable P2X3/P2X2/3 receptor antagonist, with a pIC50 of 8.0 for both human and rat P2X3, and with a pIC50 of 7.3 for human P2X2/3 .

HY-16322S

Minodronic acid-d4 YM-529-d₄	Isotope-Labeled Compounds P2X Receptor Apoptosis	Cancer
Minodronic acid-d₄ is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain .

HY-182715

PSB-10211	P2X Receptor	Neurological Disease
PSB-10211 is a P2X2 receptor antagonist with an IC₅₀ of 0.086 μM against rat P2X2 receptors. PSB-10211 inhibits ATP-mediated currents of rat P2X2 receptors expressed in Xenopus oocytes. PSB-10211 can be used in studies related to pain and urinary incontinence .

HY-186112

PSFL2915	P2X Receptor	Inflammation/Immunology
PSFL2915 is a P2X receptor inhibitor with oral effectiveness, with an IC₅₀ of 0.319 μM for human P2X3, 0.261 μM for rat *P2X2/3, and 13.3 μM for human P2X2, and exhibits ~42-fold selectivity for human P2X3* over human *P2X2. PSFL2915 inhibits human P2X3* activation by preventing allosteric tightening of the inner pocket of the head domain required for channel opening, with magnesium-dependent inhibition. PSFL2915 inhibits rat *P2X2/3* and human *P2X2* receptor activation, and has low activity against human P2X1, P2X4, and P2X7 receptors. PSFL2915 can be used for the research of chronic cough .

HY-137609A

TNP-GTP tetrasodium TNP-Guanosine 5'-triphosphate tetrasodium	Glutamate Dehydrogenase (GLDH) P2X Receptor Guanylate Cyclase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
TNP-GTP tetrasodium is a fluorescently labeled GTP (HY-113225) derivative. TNP-GTP tetrasodium can inhibit glutamate dehydrogenase (K_i = 2.7 μM). TNP-GTP tetrasodium is an antagonist of the purinergic *P2X₂* and *P2X_2/3* receptors with IC₅₀ values of 0.4 and 1.2 nM, respectively. TNP-GTP tetrasodium also inhibit rat soluble guanylyl cyclase (K_i = 11 nM) .

HY-RS09902

P2rx2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
P2rx2 Rat Pre-designed siRNA Set A contains three designed siRNAs for P2rx2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

P2rx2 Rat Pre-designed siRNA Set A P2rx2 Rat Pre-designed siRNA Set A

HY-RS09900

P2RX2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
P2RX2 Human Pre-designed siRNA Set A contains three designed siRNAs for P2RX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

P2RX2 Human Pre-designed siRNA Set A P2RX2 Human Pre-designed siRNA Set A

HY-RS09901

P2rx2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
P2rx2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for P2rx2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

P2rx2 Mouse Pre-designed siRNA Set A P2rx2 Mouse Pre-designed siRNA Set A

HY-137606

Uridine adenosine tetraphosphate UP4A	P2X Receptor	Cardiovascular Disease
Uridine adenosine tetraphosphate (UP4A) is an endothelium-derived vasoconstrictor that primarily acts through the P2X1 receptor and possibly through the P2Y2 and P2Y4 receptors. Uridine adenosine tetraphosphate can be used in the study of cardiovascular diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1441A

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

Cat. No.	Product Name	Chemical Structure

HY-16322S

Minodronic acid-d4
Minodronic acid-d₄ is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain .

P2rx2 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
P2rx2 Rat Pre-designed siRNA Set A contains three designed siRNAs for P2rx2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

P2RX2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
P2RX2 Human Pre-designed siRNA Set A contains three designed siRNAs for P2RX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

P2rx2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
P2rx2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for P2rx2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: